2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4106 In vivo CRISPR activation screening identifies OCT2 as a potent driver of durable CAR T cell persistence in B-ALL

Jongwon Yoon, PhD, Jie Ern Sim2, Matthew Shaw, PhD3, Kwee Yong, Prof4, Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath(Haem), PhD5, Paul Maciocia6
1 University College London, London, United Kingdom
2 University College London, London, United Kingdom
3 University College London, London, United Kingdom
4 University College London, London, United Kingdom
5 University College London, London, United Kingdom
6 University College London, London, United Kingdom
Background:
Relapse after CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukaemia is frequently driven by loss of functional persistence. Most persistence screens use in vitro systems, immunodeficient mice or loss-of-function designs, which can miss clinically useful gain-of-function regulators selected under intact host immune pressure. Here, we developed a targeted syngeneic CRISPR activation screen to identify transcription factors that can be co-expressed with a CAR to improve persistence.

Methods:
Splenocytes from dCas9-SAM mice were transduced with an mCD19.28z CAR and a CRISPR activation library targeting 1,607 murine transcription factors, then transferred into B6.SJL-CD45.1 mice bearing E2a-PBX1 B-ALL. sgRNA enrichment was measured in CAR T cells recovered 4 to 8 weeks after engraftment.

Results:
The in vivo screen identified OCT2 (POU2F2), a canonical B-cell transcription factor with no established role in T-cell biology, as one of the strongest drivers of long-term CAR T-cell persistence. To test this in human cells, we generated CD19.28z CAR T cells stably co-expressing human OCT2. Under repetitive NALM6 stimulation, OCT2-expressing CAR T cells showed a marked advantage over control CAR T cells, with superior survival and sustained anti-tumour activity across serial challenge, while preserving short-term killing in co-culture. This was not limited to CD28 costimulation: OCT2 produced the same persistence advantage in CD19.41BBz CAR T cells, supporting a transferable effect across CAR architectures. Crucially, OCT2 CAR T cells retained comparable tumour killing while producing slightly less cytokine and adopting a less activated profile, a combination consistent with improved functional fitness rather than nonspecific activation. After repeated tumour challenge, transcriptomic profiling showed that OCT2-expressing CAR T cells were driven toward a progenitor-exhausted, stem-like state, with increased expression of TCF7, BCL6, BACH2, SELL and SLAMF6, together with repression of the terminal exhaustion regulator TOX. The in vivo effect was also strong. In NALM6-bearing NSG mice, CD19.28z.OCT2 CAR T cells improved overall survival and achieved prolonged systemic persistence compared with control CAR T cells. After tumour rechallenge, OCT2-expressing CAR T cells retained tumour control, showing that OCT2 preserves functional competence under pressure. The clinical relevance of this programme was supported by independent single-cell datasets from paediatric and adult CD19 CAR T-cell recipients, where the OCT2 regulon was enriched in long-term persisting CAR T-cell clones from responders.

Conclusion:
These data identify OCT2 as a cross-lineage transcriptional regulator that gives CAR T cells a more durable, less overactivated functional state. The phenotype is consistent across serial stimulation, CD28z and 41BBz CAR formats, in vivo persistence, survival and tumour rechallenge, supporting OCT2 as a high-priority engineering module for improving CAR T-cell durability without sacrificing cytotoxic function.
Jongwon Yoon, PhD: No relevant conflicts of interest to declare.